How to buy Cyclo Therapeutics stock (Cyclo Therapeutics)

Cyclo Therapeutics stock is currently available to purchase as an over-the-counter (OTC) stock on the OTCQB. But many popular brokerages don't offer access to OTC stocks.

Cyclo has recently filed with the SEC to list stock on the Nasdaq Capital Market. This will make it possible to buy its stock from any major stock broker.

Our top picks for where to buy Cyclo Therapeutics stock

Buy Cyclo Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cyclo Therapeutics stock price (OTCQB: CTDH)

Use our graph to track the performance of CTDH stocks over time.

Cyclo Therapeutics shares at a glance

• Key figures

Information last updated 2021-01-22.

52-week range	$0.00 - $0.00
50-day moving average more info button	$6.10
200-day moving average more info button	$10.34
Wall St. target price	$1.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.06

Is it a good time to buy Cyclo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclo Therapeutics financials

Revenue TTM	$985,153
Gross profit TTM	$769,638
Return on assets TTM	-111.53%
Return on equity TTM	0%
Profit margin	0%
Book value	$0.03
Market Capitalization more info button	$146,185

TTM: trailing 12 months

Cyclo Therapeutics share dividends

We're not expecting Cyclo Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have Cyclo Therapeutics's shares ever split?

Cyclo Therapeutics's shares were split on a 1:100 basis on 8 December 2020 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclo Therapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Cyclo Therapeutics shares which in turn could have impacted Cyclo Therapeutics's share price.

Cyclo Therapeutics share price volatility

Over the last 12 months, Cyclo Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while Cyclo Therapeutics's is -0.8845. This would suggest that Cyclo Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cyclo Therapeutics has bucked the trend.

To put Cyclo Therapeutics's beta into context you can compare it against those of similar companies.

• Inovio Pharmaceuticals (INO.US): 0.833
• Regeneron Pharmaceuticals (REGN.US): 0.142
• Novavax (NVAX.US): 2.088

Cyclo Therapeutics overview

Cyclo Therapeutics, Inc. , a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc.

Frequently asked questions

null
What percentage of Cyclo Therapeutics is owned by insiders or institutions?
Currently 1.019% of Cyclo Therapeutics shares are held by insiders and 0.102% by institutions. How many people work for Cyclo Therapeutics?
Latest data suggests 5 work at Cyclo Therapeutics. When does the fiscal year end for Cyclo Therapeutics?
Cyclo Therapeutics's fiscal year ends in December. Where is Cyclo Therapeutics based?
Cyclo Therapeutics's address is: 6714 NW 16th Street, Gainesville, FL, United States, 32563 What is Cyclo Therapeutics's ISIN number?
Cyclo Therapeutics's international securities identification number is: US23254X1028 What is Cyclo Therapeutics's CUSIP number?
Cyclo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 23254X102